PHS
CRL icon

Pekin Hardy Strauss’s Charles River Laboratories CRL Stock Holding History

Pekin Hardy Strauss’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Sell
6,012
-145
-2% -$25.8K 0.12% 184
2026
Q1 		$1.06M Sell
6,157
-2,807
-31% -$520K 0.11% 201
2025
Q4 		$1.79M Sell
8,964
-27,096
-75% -$4.92M 0.17% 135
2025
Q3 		$5.64M Sell
36,060
-2,331
-6% -$370K 0.57% 46
2025
Q2 		$5.83M Buy
38,391
+14,996
+64% +$2M 0.66% 43
2025
Q1 		$3.52M Buy
+23,395
New +$3.92M 0.43% 64

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Pekin Hardy Strauss's CRL Position: Q2 2026 in Review

Pekin Hardy Strauss reduced its Charles River Laboratories (CRL) stake by 2.4% in Q2 2026, selling an estimated $25.8K and leaving 6,012 shares worth $1.36M. The position accounts for 0.12% of the portfolio, ranked #184.

Pekin Hardy Strauss first reported a position in CRL in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.83M in Q2 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Pekin Hardy Strauss held 6,012 shares of Charles River Laboratories worth $1.36M as of Q2 2026.
  • Pekin Hardy Strauss sold 145 Charles River Laboratories shares in Q2 2026, an estimated $25.8K.
  • Charles River Laboratories made up 0.12% of Pekin Hardy Strauss's portfolio in Q2 2026, its #184 holding.
  • Pekin Hardy Strauss first reported a position in Charles River Laboratories in Q1 2025 and has held it in 6 quarters since.
  • Pekin Hardy Strauss's Charles River Laboratories position peaked at $5.83M in Q2 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.